JNJ

190.85

-0.66%↓

ABT

126.63

+0.17%↑

MDT

93.85

-0.53%↓

VEEV

293.38

+0.69%↑

A

148.14

+0.67%↑

JNJ

190.85

-0.66%↓

ABT

126.63

+0.17%↑

MDT

93.85

-0.53%↓

VEEV

293.38

+0.69%↑

A

148.14

+0.67%↑

JNJ

190.85

-0.66%↓

ABT

126.63

+0.17%↑

MDT

93.85

-0.53%↓

VEEV

293.38

+0.69%↑

A

148.14

+0.67%↑

JNJ

190.85

-0.66%↓

ABT

126.63

+0.17%↑

MDT

93.85

-0.53%↓

VEEV

293.38

+0.69%↑

A

148.14

+0.67%↑

JNJ

190.85

-0.66%↓

ABT

126.63

+0.17%↑

MDT

93.85

-0.53%↓

VEEV

293.38

+0.69%↑

A

148.14

+0.67%↑

Search

Guardant Health Inc

Închisă

SectorSănătate

72.17 4.31

Rezumat

Modificarea prețului

24h

Curent

Minim

69.34

Maxim

72.53

Indicatori cheie

By Trading Economics

Venit

-4.7M

-100M

Vânzări

29M

232M

Marjă de profit

-43.044

Angajați

1,999

EBITDA

22M

-89M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+5.6% upside

Dividende

By Dow Jones

Următoarele câștiguri

29 oct. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

3.3B

8.8B

Deschiderea anterioară

67.86

Închiderea anterioară

72.17

Sentimentul știrilor

By Acuity

21%

79%

45 / 371 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Guardant Health Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

23 oct. 2025, 20:49 UTC

Câștiguri

Correction to Thermo Fisher Article on Oct. 22

23 oct. 2025, 23:51 UTC

Market Talk

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23 oct. 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 oct. 2025, 23:49 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23 oct. 2025, 23:37 UTC

Market Talk

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23 oct. 2025, 22:58 UTC

Market Talk

Global Energy Roundup: Market Talk

23 oct. 2025, 22:57 UTC

Market Talk

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23 oct. 2025, 22:49 UTC

Achiziții, Fuziuni, Preluări

How Trump Sparked a New Era of State Capitalism -2-

23 oct. 2025, 22:49 UTC

Achiziții, Fuziuni, Preluări

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23 oct. 2025, 22:17 UTC

Câștiguri

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23 oct. 2025, 21:41 UTC

Câștiguri

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23 oct. 2025, 21:05 UTC

Câștiguri

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23 oct. 2025, 20:50 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

23 oct. 2025, 20:50 UTC

Market Talk
Câștiguri

Auto & Transport Roundup: Market Talk

23 oct. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23 oct. 2025, 20:35 UTC

Câștiguri

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23 oct. 2025, 20:28 UTC

Câștiguri

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23 oct. 2025, 20:15 UTC

Market Talk
Câștiguri

Global Commodities Roundup: Market Talk

23 oct. 2025, 20:10 UTC

Câștiguri

Newmont Mining 3Q Adj EPS $1.71

23 oct. 2025, 20:10 UTC

Câștiguri

Newmont Mining 3Q Sales $5.52B

23 oct. 2025, 20:10 UTC

Câștiguri

Newmont Mining 3Q EPS $1.67

23 oct. 2025, 20:09 UTC

Câștiguri

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23 oct. 2025, 20:07 UTC

Market Talk
Câștiguri

Global Equities Roundup: Market Talk

23 oct. 2025, 20:07 UTC

Market Talk
Câștiguri

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23 oct. 2025, 20:07 UTC

Câștiguri

Blackstone Looks to IPOs for Investment Exits -- Update

23 oct. 2025, 20:05 UTC

Câștiguri

Intel 3Q Gross Margin 38.2% >INTC

23 oct. 2025, 20:04 UTC

Câștiguri

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23 oct. 2025, 20:04 UTC

Câștiguri

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23 oct. 2025, 20:04 UTC

Câștiguri

Intel: 4Q Guidance Excludes Altera >INTC

23 oct. 2025, 20:04 UTC

Câștiguri

Intel Sees 4Q Adj EPS 8c >INTC

Comparație

Modificare preț

Guardant Health Inc Așteptări

Obiectiv de preț

By TipRanks

5.6% sus

Prognoză pe 12 luni

Medie 71.84 USD  5.6%

Maxim 90 USD

Minim 60 USD

În baza a 21 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruGuardant Health Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

21 ratings

21

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

38.86 / 47.41Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bullish Evidence

Sentiment

By Acuity

45 / 371 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat